Alnylam Pharmaceuticals Files Second-Quarter 10-Q With SEC
The $27 billion biotechnology company submitted its quarterly financial disclosure as investors await upcoming special calls scheduled for September and October.
Quarterly Filing Submitted
Alnylam Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on July 30, marking the company's regular disclosure of financial results and operational updates for the second quarter of 2026. The Cambridge, Massachusetts-based biotechnology firm, which closed at $205.48 per share and maintains a market capitalization of approximately $27 billion, submitted the filing through the SEC's EDGAR system.
The 10-Q filing represents a mandatory quarterly disclosure for publicly traded companies, providing investors with unaudited financial statements and management's discussion of business performance, risks, and material developments during the reporting period.
Upcoming Investor Events
According to MarginX data, Alnylam has scheduled two special calls for investors in the coming months. The first is set for September 17, one day after the Federal Open Market Committee's rate decision and economic projections release on September 16. A second special call is scheduled for October 26, just ahead of the October 28 FOMC rate decision.
The timing of these calls suggests potential significant announcements or strategic updates, though the company has not disclosed the specific agenda for either event. Special calls outside of routine earnings releases often signal material corporate developments, partnership announcements, or clinical trial readouts.
Recent Insider Activity
MarginX data shows recent insider transactions at the company. Director David E. Pyott executed two separate sales, disposing of 17 shares in one transaction and 1,175 shares in another. Meanwhile, Benjamin Cravatt received an award of 4,393 shares, reflecting typical equity-based compensation arrangements common in the biotechnology sector.
Insider transactions, particularly modest sales by directors, are routine occurrences and can reflect personal financial planning rather than views on company prospects. Award grants typically align with predetermined compensation schedules.
Investors will likely monitor the upcoming special calls for clarity on the company's strategic direction and any potential catalysts following this quarterly filing.
This article was generated by MarginX from public news on 2026-07-30. It is not investment advice.